# The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial

> **NCT06439524** · PHASE3 · RECRUITING · sponsor: **Main Line Health** · enrollment: 110 (estimated)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate

## Key facts

- **NCT ID:** NCT06439524
- **Lead sponsor:** Main Line Health
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-15
- **Primary completion:** 2026-02-15
- **Final completion:** 2026-08-15
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2025-06-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06439524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06439524, "The Effect of Medical Management Following Excisional Surgery for Endometriosis: A Randomized Controlled Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06439524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*